EU medicine regulators are planning to produce catalogs of real-world data (RWD) sources and observational studies later this year or in early 2023, and are preparing to select partners who have access to such data.
The move is part of efforts to improve the transparency of observational study data and data sources and to make it easier to judge the “evidentiary value” of observational studies and RWD sources when used to assess the safety and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?